Open AccessEffectiveness and safety of amphetamine for ADHD in population between 6 and 19 years: a systematic review
Author(s) -
José Luís Calleja,
José Uribarri
Publication year - 2012
Publication title -
medwave
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.178
H-Index - 7
ISSN - 0717-6384
DOI - 10.5867/medwave.2012.08.5473
Subject(s) - politics , humanities , population , medicine , political science , psychology , psychiatry , law , environmental health , art
Introduction: Attention deficit hyperactivity disorder (ADHD) drug treatment is based on psychostimulants, and methylphenidate is still the most widely used one. Other psychostimulants used include amphetamines, hence the importance of knowing both its effectiveness and safety. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of amphetamine in ADHD in the 6-19 year-old population. Methods: A systematic review of studies that evaluated the effectiveness of interventions comparing amphetamine to methylphenidate was conducted. The outcomes measured were educational performance, psychosocial functioning, quality of life and adverse effects. The following databases were searched up to February 2012 in English and Spanish: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles that met inclusion criteria were assessed by two researchers independently. Results: Of the 114 studies found initially, four were included, among which a systematic review, a primary article and two clinical guidelines. Conclusions: The evidence on amphetamine for ADHD treatment recommends its use as an alternative to MPH. Further good-quality studies are needed